Details of the Drug Combination

General Information of Drug Combination (ID: DC1EEK3)

• Drug Combination Name: Ethinyl Estradiol + Imatinib
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Ethinyl Estradiol (DMODJ40): Small molecular drug
  Imatinib (DM7RJXL): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 5.73
  Bliss Independence Score: 5.73
  Loewe Additivity Score: 6.74
  LHighest Single Agent (HSA) Score: 6.74

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Ethinyl Estradiol

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[2]
Female hypogonadism	GA30.6	Approved	[3]
Hot flushes	GA30	Approved	[2]
Obsolete atrophic vulva	N.A.	Approved	[2]

Ethinyl Estradiol Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Agonist	[15]

Ethinyl Estradiol Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[16]

Ethinyl Estradiol Interacts with 6 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[17]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Metabolism	[18]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Metabolism	[19]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[20]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[19]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[21]

Ethinyl Estradiol Interacts with 280 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Decreases Activity	[20]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Decreases Expression	[22]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Hydroxylation	[19]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Increases Hydroxylation	[19]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Increases Hydroxylation	[19]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Expression	[16]
Sulfotransferase 1E1 (SULT1E1)	OTGPJ517	ST1E1_HUMAN	Decreases Activity	[23]
Gamma-aminobutyric acid receptor subunit pi (GABRP)	OTGKA8WS	GBRP_HUMAN	Decreases Expression	[12]
Ectoderm-neural cortex protein 1 (ENC1)	OTJEUB6U	ENC1_HUMAN	Decreases Expression	[12]
Na(+)/H(+) exchange regulatory cofactor NHE-RF1 (NHERF1)	OTFK8KDP	NHRF1_HUMAN	Increases Expression	[12]
Neuropilin-1 (NRP1)	OTCGULYV	NRP1_HUMAN	Increases Expression	[12]
Transmembrane protease serine 2 (TMPRSS2)	OTN44YQ5	TMPS2_HUMAN	Decreases Expression	[12]
Insulin-induced gene 1 protein (INSIG1)	OTZF5X1D	INSI1_HUMAN	Increases Expression	[12]
Krueppel-like factor 4 (KLF4)	OT4O9RQW	KLF4_HUMAN	Increases Expression	[12]
Band 4.1-like protein 2 (EPB41L2)	OT6UABPM	E41L2_HUMAN	Increases Expression	[12]
Tetraspanin-1 (TSPAN1)	OTZQPIYK	TSN1_HUMAN	Decreases Expression	[12]
Microfibrillar-associated protein 3-like (MFAP3L)	OTNMHSAH	MFA3L_HUMAN	Increases Expression	[12]
Short-chain dehydrogenase/reductase 3 (DHRS3)	OTSK1DTP	DHRS3_HUMAN	Increases Expression	[12]
Dysferlin (DYSF)	OTNSKJU0	DYSF_HUMAN	Decreases Expression	[12]
Gamma-butyrobetaine dioxygenase (BBOX1)	OTKEX4RK	BODG_HUMAN	Decreases Expression	[12]
Nebulette (NEBL)	OT2WH1NC	NEBL_HUMAN	Decreases Expression	[12]
ATP-dependent DNA helicase Q5 (RECQL5)	OTVZMP1Q	RECQ5_HUMAN	Decreases Expression	[12]
Sorbin and SH3 domain-containing protein 2 (SORBS2)	OTJSX44Y	SRBS2_HUMAN	Decreases Expression	[12]
Serine protease 23 (PRSS23)	OT6DQAM1	PRS23_HUMAN	Decreases Expression	[12]
NADH dehydrogenase 1 beta subcomplex subunit 6 (NDUFB6)	OTIXNT91	NDUB6_HUMAN	Increases Expression	[12]
Rap guanine nucleotide exchange factor 3 (RAPGEF3)	OTMOW4Z4	RPGF3_HUMAN	Decreases Expression	[12]
Secretoglobin family 1D member 2 (SCGB1D2)	OTSYWZAQ	SG1D2_HUMAN	Increases Expression	[12]
Aldehyde dehydrogenase 1A1 (ALDH1A1)	OTCUWZKB	AL1A1_HUMAN	Decreases Expression	[12]
Carbonic anhydrase 2 (CA2)	OTJRMUAG	CAH2_HUMAN	Increases Expression	[12]
Protein c-Fos (FOS)	OTJBUVWS	FOS_HUMAN	Increases Expression	[12]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Increases Expression	[12]
Protransforming growth factor alpha (TGFA)	OTPD1LL9	TGFA_HUMAN	Increases Expression	[12]
N-myc proto-oncogene protein (MYCN)	OTWD33K1	MYCN_HUMAN	Decreases Expression	[12]
Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCA)	OTWJTCRK	PCCA_HUMAN	Increases Expression	[12]
Alkaline phosphatase, placental type (ALPP)	OTZU4G9W	PPB1_HUMAN	Increases Expression	[12]
Collagen alpha-2(V) chain (COL5A2)	OT5VOSQE	CO5A2_HUMAN	Decreases Expression	[12]
Progesterone receptor (PGR)	OT0FZ3QE	PRGR_HUMAN	Increases Expression	[12]
Thrombospondin-1 (THBS1)	OT0ECWK3	TSP1_HUMAN	Increases Expression	[12]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Increases Expression	[12]
Interleukin-6 receptor subunit alpha (IL6R)	OTCQL07Z	IL6RA_HUMAN	Increases Expression	[12]
Matrilysin (MMP7)	OTVT3SEJ	MMP7_HUMAN	Increases Expression	[12]
Stromelysin-2 (MMP10)	OTJDWW8Q	MMP10_HUMAN	Decreases Expression	[12]
Retinol-binding protein 1 (RBP1)	OTRP1MFC	RET1_HUMAN	Decreases Expression	[12]
Tropomyosin alpha-1 chain (TPM1)	OTD73X6R	TPM1_HUMAN	Decreases Expression	[12]
Interferon alpha-inducible protein 6 (IFI6)	OTWOOAM4	IFI6_HUMAN	Decreases Expression	[12]
Alkaline phosphatase, germ cell type (ALPG)	OTCIM29R	PPBN_HUMAN	Increases Expression	[12]
Creatine kinase B-type (CKB)	OTUCKOTT	KCRB_HUMAN	Increases Expression	[12]
Insulin-like growth factor-binding protein 3 (IGFBP3)	OTIX63TX	IBP3_HUMAN	Decreases Expression	[12]
Early growth response protein 1 (EGR1)	OTCP6XGZ	EGR1_HUMAN	Increases Expression	[12]
Endothelin-2 (EDN2)	OTQ7RCPI	EDN2_HUMAN	Decreases Expression	[12]
Collagen alpha-1(V) chain (COL5A1)	OT24078H	CO5A1_HUMAN	Increases Expression	[12]
Fibroblast growth factor receptor 2 (FGFR2)	OTLOPACK	FGFR2_HUMAN	Decreases Expression	[12]
Galanin peptides (GAL)	OTB3VPTO	GALA_HUMAN	Increases Expression	[12]
Fibroblast growth factor receptor 3 (FGFR3)	OTSAXDIL	FGFR3_HUMAN	Decreases Expression	[12]
cAMP-dependent protein kinase catalytic subunit beta (PRKACB)	OT6RMDCE	KAPCB_HUMAN	Affects Expression	[12]
Prostaglandin G/H synthase 1 (PTGS1)	OTHCRLEC	PGH1_HUMAN	Decreases Expression	[12]
Insulin-like growth factor-binding protein 5 (IGFBP5)	OTRE5V0C	IBP5_HUMAN	Decreases Expression	[12]
CCN family member 2 (CCN2)	OTC39NSU	CCN2_HUMAN	Decreases Expression	[12]
Transcription factor HIVEP2 (HIVEP2)	OTVOMCW4	ZEP2_HUMAN	Decreases Expression	[12]
Sodium- and chloride-dependent taurine transporter (SLC6A6)	OT67U7G3	SC6A6_HUMAN	Decreases Expression	[12]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Increases Expression	[12]
Activin receptor type-1B (ACVR1B)	OT778HIQ	ACV1B_HUMAN	Decreases Expression	[12]
Collagen alpha-1(XV) chain (COL15A1)	OTTFKK18	COFA1_HUMAN	Increases Expression	[12]
Replication factor C subunit 3 (RFC3)	OT1MS7AO	RFC3_HUMAN	Increases Expression	[12]
Exosome RNA helicase MTR4 (MTREX)	OTSQY30V	MTREX_HUMAN	Increases Expression	[12]
G protein-activated inward rectifier potassium channel 1 (KCNJ3)	OTHQG16J	KCNJ3_HUMAN	Decreases Expression	[12]
Retinol-binding protein 2 (RBP2)	OTR8QG5V	RET2_HUMAN	Decreases Expression	[12]
LIM domain kinase 2 (LIMK2)	OTRJD7VZ	LIMK2_HUMAN	Decreases Expression	[12]
ADP-ribosylation factor 3 (ARF3)	OTYYQX85	ARF3_HUMAN	Decreases Expression	[12]
Transforming growth factor beta-2 proprotein (TGFB2)	OTC0TXEP	TGFB2_HUMAN	Decreases Expression	[12]
Phosphoserine phosphatase (PSPH)	OTV1PVAX	SERB_HUMAN	Decreases Expression	[12]
Protein jagged-1 (JAG1)	OT3LGT6K	JAG1_HUMAN	Decreases Expression	[12]
4-aminobutyrate aminotransferase, mitochondrial (ABAT)	OTXAGR7J	GABT_HUMAN	Decreases Expression	[12]
Low-density lipoprotein receptor-related protein 2 (LRP2)	OTZ6W681	LRP2_HUMAN	Decreases Expression	[12]
Large neutral amino acids transporter small subunit 1 (SLC7A5)	OT2WPVXD	LAT1_HUMAN	Increases Expression	[12]
Cyclic AMP-responsive element-binding protein 5 (CREB5)	OTJDUJPI	CREB5_HUMAN	Increases Expression	[12]
Transcription factor SOX-4 (SOX4)	OTSS40SS	SOX4_HUMAN	Decreases Expression	[12]
Amino acid transporter heavy chain SLC3A1 (SLC3A1)	OT56V01A	SLC31_HUMAN	Decreases Expression	[12]
Cadherin-18 (CDH18)	OTC06P9H	CAD18_HUMAN	Decreases Expression	[12]
Calcyphosin (CAPS)	OTC9GZ2M	CAYP1_HUMAN	Increases Expression	[12]
Transcription factor Dp-2 (TFDP2)	OTKQFX5H	TFDP2_HUMAN	Decreases Expression	[12]
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (PDE3A)	OTKUW1WT	PDE3A_HUMAN	Decreases Expression	[12]
Next to BRCA1 gene 1 protein (NBR1)	OTVRL7J9	NBR1_HUMAN	Decreases Expression	[12]
Pericentriolar material 1 protein (PCM1)	OTFM133C	PCM1_HUMAN	Decreases Expression	[12]
Neutral amino acid transporter B(0) (SLC1A5)	OTE2H26Q	AAAT_HUMAN	Increases Expression	[12]
Adiponectin (ADIPOQ)	OTNX23LE	ADIPO_HUMAN	Decreases Expression	[12]
Dual specificity protein phosphatase 5 (DUSP5)	OTH96RA7	DUS5_HUMAN	Increases Expression	[12]
Protein Dok-7 (DOK7)	OTR2V7HO	DOK7_HUMAN	Increases Expression	[12]
Protein GREB1 (GREB1)	OTU6ZA26	GREB1_HUMAN	Increases Expression	[12]
Piercer of microtubule wall 1 protein (PIERCE1)	OTONT0CN	PIRC1_HUMAN	Decreases Expression	[12]
Retrotransposon Gag-like protein 5 (RTL5)	OT9ZJR3N	RTL5_HUMAN	Decreases Expression	[12]
Protein phosphatase 1J (PPM1J)	OTM6GDJJ	PPM1J_HUMAN	Increases Expression	[12]
Immediate early response gene 5-like protein (IER5L)	OT6IG629	IER5L_HUMAN	Increases Expression	[12]
Disabled homolog 2-interacting protein (DAB2IP)	OTF456VC	DAB2P_HUMAN	Affects Expression	[12]
Muscleblind-like protein 2 (MBNL2)	OTF7CF1F	MBNL2_HUMAN	Decreases Expression	[12]
Anoctamin-1 (ANO1)	OTSREUNI	ANO1_HUMAN	Increases Expression	[12]
Proline-rich membrane anchor 1 (PRIMA1)	OT9ITT3P	PRIMA_HUMAN	Decreases Expression	[12]
Prolyl 3-hydroxylase 2 (P3H2)	OTY84H6U	P3H2_HUMAN	Decreases Expression	[12]
E3 ubiquitin-protein ligase TRIM22 (TRIM22)	OTJBLG5R	TRI22_HUMAN	Decreases Expression	[12]
Solute carrier family 25 member 45 (SLC25A45)	OTP7EAUM	S2545_HUMAN	Decreases Expression	[12]
PACRG-like protein (PACRGL)	OT5DEP0X	PACRL_HUMAN	Increases Expression	[12]
N-acetylaspartate synthetase (NAT8L)	OTA96AVN	NAT8L_HUMAN	Decreases Expression	[12]
Retinoic acid-induced protein 3 (GPRC5A)	OTPOCWR7	RAI3_HUMAN	Decreases Expression	[12]
Two pore channel protein 2 (TPCN2)	OTLAF3ED	TPC2_HUMAN	Decreases Expression	[12]
LIM domain only protein 3 (LMO3)	OTR7AJHN	LMO3_HUMAN	Decreases Expression	[12]
DEP domain-containing mTOR-interacting protein (DEPTOR)	OTCBP1BT	DPTOR_HUMAN	Increases Expression	[12]
Epidermal growth factor receptor kinase substrate 8-like protein 1 (EPS8L1)	OT83O8WI	ES8L1_HUMAN	Decreases Expression	[12]
Complexin-3 (CPLX3)	OT0YTMN2	CPLX3_HUMAN	Decreases Expression	[12]
Histone acetyltransferase KAT2B (KAT2B)	OTWQITWK	KAT2B_HUMAN	Decreases Expression	[12]
Protein kinase C-binding protein NELL1 (NELL1)	OTF3TX3N	NELL1_HUMAN	Decreases Expression	[12]
LIM/homeobox protein Lhx4 (LHX4)	OTVX3J6S	LHX4_HUMAN	Increases Expression	[12]
E3 ubiquitin-protein ligase MIB2 (MIB2)	OTJCC3HS	MIB2_HUMAN	Decreases Expression	[12]
Dedicator of cytokinesis protein 10 (DOCK10)	OTI3MBLV	DOC10_HUMAN	Decreases Expression	[12]
Galactose mutarotase (GALM)	OT7UPL4D	GALM_HUMAN	Decreases Expression	[12]
Endoplasmic reticulum resident protein 27 (ERP27)	OTVMGE2H	ERP27_HUMAN	Decreases Expression	[12]
Hedgehog-interacting protein (HHIP)	OT77RQYS	HHIP_HUMAN	Decreases Expression	[12]
TSC22 domain family protein 3 (TSC22D3)	OT03UM03	T22D3_HUMAN	Decreases Expression	[12]
Neurturin (NRTN)	OT4PAKUY	NRTN_HUMAN	Increases Expression	[12]
Ras-like protein family member 11B (RASL11B)	OTHEVZS6	RSLBB_HUMAN	Decreases Expression	[12]
Mitochondrial ribosome-associated GTPase 1 (MTG1)	OTC9U1LI	MTG1_HUMAN	Decreases Expression	[12]
Melanophilin (MLPH)	OT7ADCXL	MELPH_HUMAN	Increases Expression	[12]
RNA-binding protein 24 (RBM24)	OTQI1AR1	RBM24_HUMAN	Increases Expression	[12]
Keratin-associated protein 2-1 (KRTAP2-1)	OTV1SGF2	KRA21_HUMAN	Decreases Expression	[12]
Keratin, type I cytoskeletal 23 (KRT23)	OTQW6UAG	K1C23_HUMAN	Decreases Expression	[12]
Cysteine-rich secretory protein LCCL domain-containing 1 (CRISPLD1)	OT38HXJP	CRLD1_HUMAN	Increases Expression	[12]
Aryl hydrocarbon receptor nuclear translocator 2 (ARNT2)	OTAQD3YV	ARNT2_HUMAN	Decreases Expression	[12]
Plexin-A4 (PLXNA4)	OT5XKB3Q	PLXA4_HUMAN	Decreases Expression	[12]
Palmdelphin (PALMD)	OTRLOZ4Y	PALMD_HUMAN	Decreases Expression	[12]
Transcription and mRNA export factor ENY2 (ENY2)	OTTNU8RK	ENY2_HUMAN	Decreases Expression	[12]
Signal peptide, CUB and EGF-like domain-containing protein 2 (SCUBE2)	OT661S7D	SCUB2_HUMAN	Decreases Expression	[12]
Cytochrome P450 26B1 (CYP26B1)	OT92XA92	CP26B_HUMAN	Decreases Expression	[12]
Olfactomedin-like protein 3 (OLFML3)	OTDN45FN	OLFL3_HUMAN	Increases Expression	[12]
Cytokine-inducible SH2-containing protein (CISH)	OT8T5NYL	CISH_HUMAN	Increases Expression	[12]
ATPase family AAA domain-containing protein 3A (ATAD3A)	OTWF6HBP	ATD3A_HUMAN	Decreases Expression	[12]
Kv channel-interacting protein 1 (KCNIP1)	OTGLGK1R	KCIP1_HUMAN	Decreases Expression	[12]
Denticleless protein homolog (DTL)	OTC29RYE	DTL_HUMAN	Increases Expression	[12]
Peroxisomal sarcosine oxidase (PIPOX)	OTWTCOTN	SOX_HUMAN	Increases Expression	[12]
A disintegrin and metalloproteinase with thrombospondin motifs 9 (ADAMTS9)	OTV3Q0DS	ATS9_HUMAN	Increases Expression	[12]
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A)	OTHCDQ22	PRGC1_HUMAN	Decreases Expression	[12]
Dickkopf-related protein 3 (DKK3)	OTDU94EY	DKK3_HUMAN	Decreases Expression	[12]
Protein NDRG2 (NDRG2)	OT5L6KD7	NDRG2_HUMAN	Decreases Expression	[12]
Rho family-interacting cell polarization regulator 2 (RIPOR2)	OTXB6LIR	RIPR2_HUMAN	Decreases Expression	[12]
Transcription factor HES-2 (HES2)	OTMWY2KV	HES2_HUMAN	Increases Expression	[12]
Tolloid-like protein 2 (TLL2)	OTHZ4TBL	TLL2_HUMAN	Increases Expression	[12]
Metallothionein-2 (MT2A)	OTHOACHD	MT2_HUMAN	Increases Expression	[22]
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Affects Activity	[22]
S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1)	OTX8L3M5	SAHH2_HUMAN	Affects Expression	[13]
Putative hydrolase DDAH2 (DDAH2)	OT8Q40G2	DDAH2_HUMAN	Affects Expression	[13]
Integrin beta-3 (ITGB3)	OTWCK1K6	ITB3_HUMAN	Affects Expression	[13]
Small integral membrane protein 6 (SMIM6)	OTRGL3O1	SMIM6_HUMAN	Affects Expression	[13]
Heat shock 70 kDa protein 1A (HSPA1A)	OTKGIE76	HS71A_HUMAN	Affects Expression	[13]
Integrin beta-6 (ITGB6)	OTI3DJ7U	ITB6_HUMAN	Affects Expression	[13]
Deoxyribonuclease-1 (DNASE1)	OTM4KWB3	DNAS1_HUMAN	Affects Expression	[13]
G0/G1 switch protein 2 (G0S2)	OT8FL49L	G0S2_HUMAN	Affects Expression	[13]
G1/S-specific cyclin-D2 (CCND2)	OTDULQF9	CCND2_HUMAN	Affects Expression	[13]
Homeobox protein MOX-1 (MEOX1)	OTJEMT2D	MEOX1_HUMAN	Affects Expression	[13]
Diacylglycerol kinase epsilon (DGKE)	OTWS86AS	DGKE_HUMAN	Affects Expression	[13]
Cadherin-6 (CDH6)	OT81Y80S	CADH6_HUMAN	Affects Expression	[13]
Phospholipid-transporting ATPase ID (ATP8B2)	OTH5WJ09	AT8B2_HUMAN	Affects Expression	[13]
Transgelin (TAGLN)	OTAEZ0KP	TAGL_HUMAN	Affects Expression	[13]
Programmed cell death protein 4 (PDCD4)	OTZ6NXUX	PDCD4_HUMAN	Affects Expression	[13]
Sclerostin domain-containing protein 1 (SOSTDC1)	OTAKDNSM	SOSD1_HUMAN	Affects Expression	[13]
Transmembrane protein 64 (TMEM64)	OTO9IDFD	TMM64_HUMAN	Affects Expression	[13]
Echinoderm microtubule-associated protein-like 6 (EML6)	OTE1MUQS	EMAL6_HUMAN	Affects Expression	[13]
PX domain-containing protein kinase-like protein (PXK)	OTSP1WLK	PXK_HUMAN	Affects Expression	[13]
Protein limb expression 1 homolog (LIX1)	OT1CPNCC	LIX1_HUMAN	Affects Expression	[13]
Uncharacterized protein FAM241A (FAM241A)	OTC12ETA	F241A_HUMAN	Affects Expression	[13]
RalBP1-associated Eps domain-containing protein 2 (REPS2)	OTSE3TRP	REPS2_HUMAN	Affects Expression	[13]
Syntaxin-binding protein 6 (STXBP6)	OTUEKTIP	STXB6_HUMAN	Affects Expression	[13]
POC1 centriolar protein homolog B (POC1B)	OTDIMIRZ	POC1B_HUMAN	Affects Expression	[13]
Solute carrier family 2, facilitated glucose transporter member 12 (SLC2A12)	OT0EDNV9	GTR12_HUMAN	Affects Expression	[13]
Pleckstrin homology-like domain family A member 1 (PHLDA1)	OTFTWMIQ	PHLA1_HUMAN	Affects Expression	[13]
Peroxidasin homolog (PXDN)	OTFGGM9R	PXDN_HUMAN	Affects Expression	[13]
Secreted frizzled-related protein 3 (FRZB)	OTTO3DPY	SFRP3_HUMAN	Affects Expression	[13]
DNA endonuclease RBBP8 (RBBP8)	OTRHJ3GI	CTIP_HUMAN	Affects Expression	[13]
Transmembrane protease serine 4 (TMPRSS4)	OTCCGY2K	TMPS4_HUMAN	Affects Expression	[13]
Cdc42 effector protein 3 (CDC42EP3)	OTUZ3U9Z	BORG2_HUMAN	Affects Expression	[13]
Teneurin-1 (TENM1)	OTSKSU4V	TEN1_HUMAN	Affects Expression	[13]
RNA polymerase II elongation factor ELL2 (ELL2)	OTZJRTFM	ELL2_HUMAN	Affects Expression	[14]
Mothers against decapentaplegic homolog 6 (SMAD6)	OTUZZWUD	SMAD6_HUMAN	Affects Expression	[14]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Increases Activity	[24]
RAS guanyl-releasing protein 1 (RASGRP1)	OTX9WN2E	GRP1_HUMAN	Affects Expression	[14]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Expression	[25]
Cytochrome c oxidase subunit 3 (COX3)	OTNNGBYJ	COX3_HUMAN	Increases Expression	[26]
Prothrombin (F2)	OTNFSM49	THRB_HUMAN	Increases Expression	[27]
Plasminogen (PLG)	OTWWIPPY	PLMN_HUMAN	Increases Expression	[28]
Renin (REN)	OT52GZR2	RENI_HUMAN	Increases Activity	[29]
ATP synthase subunit a (ATP6)	OTPHOGLX	ATP6_HUMAN	Increases Expression	[26]
Antithrombin-III (SERPINC1)	OTDFATG0	ANT3_HUMAN	Decreases Activity	[28]
Angiotensinogen (AGT)	OTBZLYR3	ANGT_HUMAN	Increases Expression	[29]
Low-density lipoprotein receptor (LDLR)	OTH559LU	LDLR_HUMAN	Increases Expression	[30]
Follitropin subunit beta (FSHB)	OTGLS283	FSHB_HUMAN	Decreases Expression	[31]
Lutropin subunit beta (LHB)	OT5GBOVJ	LSHB_HUMAN	Decreases Activity	[32]
Somatotropin (GH1)	OT92RTRD	SOMA_HUMAN	Increases Expression	[31]
Insulin-like growth factor II (IGF2)	OTJ4O6MW	IGF2_HUMAN	Increases Expression	[33]
C-reactive protein (CRP)	OT0RFT8F	CRP_HUMAN	Increases Expression	[34]
Estrogen receptor (ESR1)	OTKLU61J	ESR1_HUMAN	Increases Expression	[35]
Trefoil factor 1 (TFF1)	OTCYQH4F	TFF1_HUMAN	Increases Expression	[36]
Histidine-rich glycoprotein (HRG)	OTPLUFOG	HRG_HUMAN	Decreases Expression	[37]
Sex hormone-binding globulin (SHBG)	OTPWU5IW	SHBG_HUMAN	Increases Expression	[38]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Affects Activity	[39]
Insulin-like growth factor I (IGF1)	OTIIZR61	IGF1_HUMAN	Decreases Expression	[31]
Endothelin-1 (EDN1)	OTZCACEG	EDN1_HUMAN	Affects Expression	[14]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Affects Expression	[40]
Thrombomodulin (THBD)	OT8VHLKY	TRBM_HUMAN	Decreases Expression	[27]
Vitamin K-dependent protein S (PROS1)	OTXQWNOI	PROS_HUMAN	Decreases Expression	[28]
Transcription factor Sp1 (SP1)	OTISPT4X	SP1_HUMAN	Increases Activity	[41]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Affects Expression	[14]
Coagulation factor VII (F7)	OTGNJ97M	FA7_HUMAN	Increases Expression	[27]
Osteopontin (SPP1)	OTJGC23Y	OSTP_HUMAN	Affects Expression	[14]
Chromogranin-A (CHGA)	OTXYX5JH	CMGA_HUMAN	Affects Expression	[14]
Serine/threonine-protein kinase pim-1 (PIM1)	OTWEKXTU	PIM1_HUMAN	Affects Expression	[14]
Keratin, type II cytoskeletal 5 (KRT5)	OTVGI9HT	K2C5_HUMAN	Affects Expression	[14]
Beta-1,4-galactosyltransferase 1 (B4GALT1)	OTBCXEK7	B4GT1_HUMAN	Increases Expression	[42]
Fos-related antigen 1 (FOSL1)	OT9YTYMB	FOSL1_HUMAN	Affects Expression	[14]
Gap junction alpha-1 protein (GJA1)	OTT94MKL	CXA1_HUMAN	Increases Expression	[43]
Insulin-like growth factor-binding protein 2 (IGFBP2)	OTG1P60E	IBP2_HUMAN	Decreases Expression	[33]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3)	OTC1UOHP	ATF3_HUMAN	Increases Expression	[44]
Myelin and lymphocyte protein (MAL)	OTBM30SW	MAL_HUMAN	Affects Expression	[14]
Insulin-like growth factor-binding protein 4 (IGFBP4)	OT2HZRBD	IBP4_HUMAN	Increases Expression	[33]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Increases Activity	[45]
Insulin-like growth factor-binding protein complex acid labile subunit (IGFALS)	OTTWCZYM	ALS_HUMAN	Decreases Expression	[31]
ETS translocation variant 5 (ETV5)	OTE2OBM4	ETV5_HUMAN	Affects Expression	[14]
Radiation-inducible immediate-early gene IEX-1 (IER3)	OTZJI5FZ	IEX1_HUMAN	Affects Expression	[14]
Solute carrier organic anion transporter family member 1A2 (SLCO1A2)	OTO70C5O	SO1A2_HUMAN	Decreases Expression	[25]
Stromal cell-derived factor 1 (CXCL12)	OT2QX5LL	SDF1_HUMAN	Increases Expression	[46]
NADP-dependent malic enzyme (ME1)	OTSVEUQE	MAOX_HUMAN	Affects Expression	[14]
Glutamate--cysteine ligase catalytic subunit (GCLC)	OTESDI4D	GSH1_HUMAN	Affects Expression	[14]
Cysteine--tRNA ligase, cytoplasmic (CARS1)	OTOUZF6O	SYCC_HUMAN	Affects Expression	[14]
Serine--tRNA ligase, cytoplasmic (SARS1)	OTFKXQ1O	SYSC_HUMAN	Affects Expression	[14]
CCAAT/enhancer-binding protein delta (CEBPD)	OTNBIPMY	CEBPD_HUMAN	Affects Expression	[14]
Inhibin beta E chain (INHBE)	OTOI2NYG	INHBE_HUMAN	Affects Expression	[14]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)	OTOWDUNT	PTEN_HUMAN	Affects Expression	[14]
Transformer-2 protein homolog beta (TRA2B)	OTZYQW52	TRA2B_HUMAN	Increases Expression	[47]
Small ribosomal subunit protein RACK1 (RACK1)	OTZBCQ1U	RACK1_HUMAN	Increases Expression	[48]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Increases Expression	[49]
Schlafen family member 5 (SLFN5)	OTT1AESL	SLFN5_HUMAN	Affects Expression	[14]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1)	OTXEE550	APR_HUMAN	Affects Expression	[14]
Four and a half LIM domains protein 2 (FHL2)	OT0OAYWT	FHL2_HUMAN	Affects Expression	[14]
Hepatic sodium/bile acid cotransporter (SLC10A1)	OTUJVMCL	NTCP_HUMAN	Decreases Expression	[25]
Nuclear receptor subfamily 1 group I member 3 (NR1I3)	OTS3SGH7	NR1I3_HUMAN	Increases Activity	[50]
Advanced glycosylation end product-specific receptor (AGER)	OTPY0IH7	RAGE_HUMAN	Increases Expression	[41]
Erythroferrone (ERFE)	OTSES1HA	ERFE_HUMAN	Affects Expression	[14]
FYVE, RhoGEF and PH domain-containing protein 3 (FGD3)	OTIH6283	FGD3_HUMAN	Affects Expression	[14]
Na(+)/H(+) exchange regulatory cofactor NHE-RF3 (PDZK1)	OTGFK4MH	NHRF3_HUMAN	Increases Expression	[42]
Early estrogen-induced gene 1 protein (EEIG1)	OT2BMEAE	EEIG1_HUMAN	Increases Expression	[42]
Very-long-chain (HACD2)	OTAZO9F6	HACD2_HUMAN	Affects Expression	[14]
Retrotransposon-derived protein PEG10 (PEG10)	OTWD2278	PEG10_HUMAN	Affects Expression	[14]
Ly6/PLAUR domain-containing protein 1 (LYPD1)	OT0HSGML	LYPD1_HUMAN	Affects Expression	[14]
Scavenger receptor class B member 1 (SCARB1)	OTAE1UA1	SCRB1_HUMAN	Affects Splicing	[47]
Stonin-2 (STON2)	OT01JHHE	STON2_HUMAN	Affects Expression	[14]
Protein NDRG1 (NDRG1)	OTVO66BO	NDRG1_HUMAN	Affects Expression	[14]
Estrogen receptor beta (ESR2)	OTXNR2WQ	ESR2_HUMAN	Increases Activity	[51]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Decreases Expression	[25]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1)	OT2363Z9	T53I1_HUMAN	Affects Expression	[14]
Mediator of RNA polymerase II transcription subunit 8 (MED8)	OTSIZ1I7	MED8_HUMAN	Affects Expression	[14]
Bile acid receptor (NR1H4)	OTWZLPTB	NR1H4_HUMAN	Decreases Expression	[25]
Tribbles homolog 3 (TRIB3)	OTG5OS7X	TRIB3_HUMAN	Affects Expression	[14]
G-protein coupled estrogen receptor 1 (GPER1)	OTUK0TDC	GPER1_HUMAN	Increases Expression	[35]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Decreases Expression	[52]
Protein associated with UVRAG as autophagy enhancer (RUBCNL)	OTMQIDOI	PACER_HUMAN	Affects Expression	[14]
Tetratricopeptide repeat protein 12 (TTC12)	OTDB24YV	TTC12_HUMAN	Affects Expression	[14]
Solute carrier family 40 member 1 (SLC40A1)	OT8RV2VY	S40A1_HUMAN	Affects Expression	[14]
Matrix-remodeling-associated protein 5 (MXRA5)	OTXZBWCU	MXRA5_HUMAN	Affects Expression	[14]
Signal-induced proliferation-associated 1-like protein 2 (SIPA1L2)	OT8NJE5D	SI1L2_HUMAN	Affects Expression	[14]
Kelch-like protein 14 (KLHL14)	OTYOS55H	KLH14_HUMAN	Affects Expression	[14]
Transcription factor MafF (MAFF)	OT9B7MX0	MAFF_HUMAN	Affects Expression	[14]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Affects Expression	[14]
Proton-coupled zinc antiporter SLC30A1 (SLC30A1)	OTY8J0S4	ZNT1_HUMAN	Affects Expression	[14]
SET-binding protein (SETBP1)	OTKGCOSR	SETBP_HUMAN	Affects Expression	[14]
Sulfotransferase 2A1 (SULT2A1)	OT0ISKQ4	ST2A1_HUMAN	Increases Metabolism	[53]
Sulfotransferase 1A1 (SULT1A1)	OT0K7JIE	ST1A1_HUMAN	Increases Metabolism	[53]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Increases Uptake	[54]
Cytochrome P450 (CYP2B)	OTDDG81I	Q14097_HUMAN	Increases ADR	[55]
Sulfotransferase 1B1 (SULT1B1)	OTH0RQYA	ST1B1_HUMAN	Increases Metabolism	[53]
Sulfotransferase 1A3 (SULT1A4)	OTHJ8WWV	ST1A3_HUMAN	Increases Sulfation	[56]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Increases Hydroxylation	[19]
Fibroblast growth factor 4 (FGF4)	OTNVV3ZG	FGF4_HUMAN	Increases ADR	[55]
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Affects Metabolism	[57]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Increases Hydroxylation	[19]

Indication(s) of Imatinib

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Approved	[4]
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive	N.A.	Approved	[5]
Choroidal neovascularization	9B76	Approved	[5]
Chronic eosinophilic leukemia	N.A.	Approved	[5]
Chronic myelogenous leukaemia	2A20.0	Approved	[6]
Chronic myeloid leukaemia	2A20	Approved	[7]
Dermatofibrosarcoma protuberans	N.A.	Approved	[5]
Gastrointestinal stromal tumour	2B5B	Approved	[5]
Leukemia	N.A.	Approved	[5]
Malignant peripheral nerve sheath tumor	N.A.	Approved	[5]
Myeloproliferative neoplasm	2A20	Approved	[5]
Pulmonary hypertension	BB01	Approved	[5]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[8]
Intestinal cancer	2C0Z	Phase 3	[6]
Lung cancer	2C25.0	Phase 2	[6]
Idiopathic hypereosinophilic syndrome	N.A.	Investigative	[5]
Middle East Respiratory Syndrome (MERS)	1D64	Investigative	[9]
Scleroderma	4A42	Investigative	[5]
Severe acute respiratory syndrome (SARS)	1D65	Investigative	[9]
Systemic mastocytosis	2A21.0	Investigative	[10]

Imatinib Interacts with 5 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Mcl-1 messenger RNA (MCL-1 mRNA)	TTN6ORK	MCL1_HUMAN	.	[10]
Fusion protein Bcr-Abl (Bcr-Abl)	TTS7G69	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[61]
Platelet-derived growth factor receptor (PDGFR)	TTI2WET	NOUNIPROTAC	Inhibitor	[61]
Tyrosine-protein kinase Kit (KIT)	TTX41N9	KIT_HUMAN	Inhibitor	[61]
HUMAN fusion protein Bcr-Abl (Bcr-Abl)	TTE63HY	BCR_HUMAN/ABL1_HUMAN	Inhibitor	[9]

Imatinib Interacts with 6 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[62]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[63]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[64]
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[65]
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[66]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[64]

Imatinib Interacts with 8 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[67]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Metabolism	[68]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Metabolism	[69]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[70]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Metabolism	[71]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[72]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[73]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Metabolism	[69]

Imatinib Interacts with 95 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Decreases Methylation	[74]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Decreases Methylation	[74]
Cytochrome P450 3A7 (CYP3A7)	OTTCDHHM	CP3A7_HUMAN	Decreases Methylation	[74]
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Decreases Methylation	[74]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Increases Expression	[75]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Expression	[75]
Aldehyde dehydrogenase, mitochondrial (ALDH2)	OTKJ9I3N	ALDH2_HUMAN	Decreases Expression	[76]
Eukaryotic translation initiation factor 4E (EIF4E)	OTDAWNLA	IF4E_HUMAN	Decreases Expression	[76]
Fructose-bisphosphate aldolase C (ALDOC)	OTEC13I5	ALDOC_HUMAN	Decreases Expression	[76]
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial (PDHB)	OT2NHE5E	ODPB_HUMAN	Decreases Expression	[76]
Cyclin-dependent kinase 4 (CDK4)	OT7EP05T	CDK4_HUMAN	Decreases Expression	[76]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Decreases Expression	[76]
Ribosomal protein S6 kinase beta-1 (RPS6KB1)	OTAELNGX	KS6B1_HUMAN	Decreases Expression	[76]
Eukaryotic translation initiation factor 4B (EIF4B)	OTE8TXA8	IF4B_HUMAN	Decreases Expression	[76]
Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1)	OT5BZ1J9	P85A_HUMAN	Decreases Expression	[76]
G1/S-specific cyclin-D3 (CCND3)	OTNKPQ22	CCND3_HUMAN	Decreases Expression	[76]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Expression	[76]
Hexokinase-4 (GCK)	OTR3Q0NN	HXK4_HUMAN	Decreases Expression	[76]
Serine/threonine-protein kinase mTOR (MTOR)	OTHH8KU7	MTOR_HUMAN	Decreases Expression	[76]
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PPP2CA)	OT83PT85	PP2AA_HUMAN	Increases Expression	[76]
Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1)	OTHBQVD5	4EBP1_HUMAN	Decreases Expression	[76]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[77]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Decreases Expression	[78]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[79]
Autophagy-related protein 13 (ATG13)	OTYMHNEJ	ATG13_HUMAN	Increases Phosphorylation	[58]
Platelet-derived growth factor subunit B (PDGFB)	OTMFMFC3	PDGFB_HUMAN	Decreases Expression	[80]
Interferon gamma (IFNG)	OTXG9JM7	IFNG_HUMAN	Increases Expression	[81]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Increases Secretion	[82]
Keratin, type I cytoskeletal 14 (KRT14)	OTUVZ1DW	K1C14_HUMAN	Increases Expression	[83]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[84]
Heat shock protein beta-1 (HSPB1)	OTHFZ8ED	HSPB1_HUMAN	Increases Expression	[79]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Decreases Activity	[85]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Increases Expression	[79]
Tyrosine-protein kinase Lck (LCK)	OT883FG9	LCK_HUMAN	Decreases Phosphorylation	[86]
Cyclin-dependent kinase 1 (CDK1)	OTW1SC2N	CDK1_HUMAN	Decreases Expression	[81]
Cathepsin B (CTSB)	OTP9G5QB	CATB_HUMAN	Increases Expression	[58]
Proto-oncogene tyrosine-protein kinase receptor Ret (RET)	OTLU040A	RET_HUMAN	Decreases Phosphorylation	[87]
ATP-dependent 6-phosphofructokinase, muscle type (PFKM)	OT1QY9JM	PFKAM_HUMAN	Decreases Expression	[88]
Platelet-derived growth factor receptor beta (PDGFRB)	OTYSNK9Q	PGFRB_HUMAN	Decreases Expression	[80]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[89]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases Expression	[79]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[90]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)	OTA675TJ	GTR1_HUMAN	Decreases Expression	[84]
Breakpoint cluster region protein (BCR)	OTCN76C1	BCR_HUMAN	Decreases Activity	[60]
Lysosome-associated membrane glycoprotein 1 (LAMP1)	OTYE92QY	LAMP1_HUMAN	Increases Expression	[58]
Ornithine decarboxylase (ODC1)	OTNDAGRR	DCOR_HUMAN	Increases Expression	[79]
Keratin, type II cytoskeletal 5 (KRT5)	OTVGI9HT	K2C5_HUMAN	Increases Expression	[83]
Tissue factor (F3)	OT3MSU3B	TF_HUMAN	Increases Expression	[91]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Expression	[92]
Platelet-derived growth factor receptor alpha (PDGFRA)	OTDJXUCN	PGFRA_HUMAN	Decreases Expression	[80]
CCAAT/enhancer-binding protein beta (CEBPB)	OTM9MQIA	CEBPB_HUMAN	Increases Expression	[79]
Histidine decarboxylase (HDC)	OT4WA5YQ	DCHS_HUMAN	Decreases Expression	[93]
Transcription factor EB (TFEB)	OTJUJJQY	TFEB_HUMAN	Affects Localization	[58]
Fibroblast growth factor receptor 3 (FGFR3)	OTSAXDIL	FGFR3_HUMAN	Decreases Expression	[94]
Insulin-like growth factor-binding protein 4 (IGFBP4)	OT2HZRBD	IBP4_HUMAN	Increases Expression	[79]
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Increases Secretion	[95]
Interleukin-4 receptor subunit alpha (IL4R)	OTTXOTCW	IL4RA_HUMAN	Increases Expression	[79]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Decreases Expression	[81]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Increases Phosphorylation	[79]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Phosphorylation	[86]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Phosphorylation	[86]
Caspase-1 (CASP1)	OTZ3YQFU	CASP1_HUMAN	Increases Cleavage	[82]
Catenin beta-1 (CTNNB1)	OTZ932A3	CTNB1_HUMAN	Decreases Expression	[96]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[97]
Crk-like protein (CRKL)	OTOYSD1R	CRKL_HUMAN	Decreases Phosphorylation	[98]
Glycogen synthase kinase-3 beta (GSK3B)	OTL3L14B	GSK3B_HUMAN	Increases Phosphorylation	[58]
Hexokinase-2 (HK2)	OTC0GCQO	HXK2_HUMAN	Decreases Expression	[88]
Small ribosomal subunit protein eS6 (RPS6)	OTT4D1LN	RS6_HUMAN	Decreases Phosphorylation	[58]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Increases Expression	[79]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Decreases Expression	[96]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[90]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[99]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	OT2YYI1A	MCL1_HUMAN	Decreases Expression	[89]
Forkhead box protein M1 (FOXM1)	OT5887KR	FOXM1_HUMAN	Decreases Expression	[96]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Decreases Activity	[100]
Sequestosome-1 (SQSTM1)	OTGY5D5J	SQSTM_HUMAN	Increases Expression	[58]
Beclin-1 (BECN1)	OT4X293M	BECN1_HUMAN	Increases Expression	[58]
Nuclear receptor subfamily 0 group B member 2 (NR0B2)	OT7UVICX	NR0B2_HUMAN	Increases Expression	[101]
NGFI-A-binding protein 2 (NAB2)	OTG4BDF3	NAB2_HUMAN	Increases Expression	[79]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Decreases Expression	[102]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Decreases Activity	[85]
TRAF family member-associated NF-kappa-B activator (TANK)	OTZSGFIK	TANK_HUMAN	Increases Expression	[79]
NACHT, LRR and PYD domains-containing protein 3 (NLRP3)	OTZM6MHU	NLRP3_HUMAN	Increases Expression	[82]
Bile acid receptor (NR1H4)	OTWZLPTB	NR1H4_HUMAN	Increases Activity	[101]
Docking protein 1 (DOK1)	OTGVRLW6	DOK1_HUMAN	Decreases Phosphorylation	[103]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B)	OTUYHB84	MLP3B_HUMAN	Increases Expression	[58]
Transcription factor SOX-17 (SOX17)	OT9H4WWE	SOX17_HUMAN	Decreases Localization	[104]
V-type proton ATPase subunit H (ATP6V1H)	OTX17GQ9	VATH_HUMAN	Increases Expression	[58]
Tyrosine-protein kinase ABL1 (ABL1)	OT09YVXH	ABL1_HUMAN	Increases Response To Substance	[105]
LYR motif-containing protein 9 (LYRM9)	OT1MILTK	LYRM9_HUMAN	Affects Response To Substance	[106]
Leptin (LEP)	OT5Q7ODW	LEP_HUMAN	Increases ADR	[55]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Response To Substance	[107]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Increases Response To Substance	[108]
Tyrosine-protein kinase Lyn (LYN)	OTP686K2	LYN_HUMAN	Decreases Response To Substance	[98]
Serine/threonine-protein kinase PLK1 (PLK1)	OTRZX45T	PLK1_HUMAN	Increases Response To Substance	[89]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Ethinyl estradiol FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7071).
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Imatinib FDA Label
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687).
• [7] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 078340.
• [8] ClinicalTrials.gov (NCT04356495) Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19). U.S. National Institutes of Health.
• [9] Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
• [10] Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
• [11] Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos. 2007 Dec;35(12):2270-80.
• [12] The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
• [13] Dose- and time-dependent transcriptional response of Ishikawa cells exposed to genistein. Toxicol Sci. 2016 May;151(1):71-87.
• [14] The genomic response of Ishikawa cells to bisphenol A exposure is dose- and time-dependent. Toxicology. 2010 Apr 11;270(2-3):137-49. doi: 10.1016/j.tox.2010.02.008. Epub 2010 Feb 17.
• [15] 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8.
• [16] P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
• [17] Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metab Rev. 2004 Oct;36(3-4):497-509.
• [18] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [19] The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
• [20] Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
• [21] The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003 Aug;56(2):232-7.
• [22] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [23] Development and validation of a fluorescence HPLC-based screening assay for inhibition of human estrogen sulfotransferase. Anal Biochem. 2006 Oct 1;357(1):85-92.
• [24] Development of a common carp (Cyprinus carpio) pregnane X receptor (cPXR) transactivation reporter assay and its activation by azole fungicides and pharmaceutical chemicals. Toxicol In Vitro. 2017 Jun;41:114-122. doi: 10.1016/j.tiv.2017.02.023. Epub 2017 Mar 1.
• [25] UDCA and CDCA alleviate 17-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats. Toxicol Appl Pharmacol. 2016 Nov 15;311:12-25. doi: 10.1016/j.taap.2016.10.011. Epub 2016 Oct 12.
• [26] Enhanced levels of several mitochondrial mRNA transcripts and mitochondrial superoxide production during ethinyl estradiol-induced hepatocarcinogenesis and after estrogen treatment of HepG2 cells. Carcinogenesis. 1998 Dec;19(12):2187-93. doi: 10.1093/carcin/19.12.2187.
• [27] Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost. 1996 Nov;76(5):729-34.
• [28] Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab. 2007 Jun;92(6):2074-9. doi: 10.1210/jc.2007-0026. Epub 2007 Mar 20.
• [29] Influence of the M235T polymorphism of human angiotensinogen (AGT) on plasma AGT and renin concentrations after ethinylestradiol administration. J Clin Endocrinol Metab. 2000 Nov;85(11):4331-7. doi: 10.1210/jcem.85.11.6932.
• [30] Study of low-density lipoprotein receptor regulation by oral (steroid) contraceptives: desogestrel, levonorgestrel and ethinyl estradiol in JEG-3 cell line and placental tissue. Contraception. 2007 Oct;76(4):297-305. doi: 10.1016/j.contraception.2007.06.011. Epub 2007 Sep 14.
• [31] Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab. 2000 May;85(5):1918-22. doi: 10.1210/jcem.85.5.6527.
• [32] Estrogenic Compounds or Adiponectin Inhibit Cyclic AMP Response to Human Luteinizing Hormone in Mouse Leydig Tumor Cells. Biology (Basel). 2019 Jun 11;8(2):45. doi: 10.3390/biology8020045.
• [33] Ethinylestradiol and testosterone have divergent effects on circulating IGF system components in adolescents with constitutional tall stature. Eur J Endocrinol. 2005 Apr;152(4):597-604. doi: 10.1530/eje.1.01880.
• [34] Oral ethinyl estradiol, but not transdermal 17beta-estradiol, increases plasma C-reactive protein levels in men. Thromb Haemost. 2000 Aug;84(2):359-60.
• [35] Prediction of the combined effects of multiple estrogenic chemicals on MCF-7 human breast cancer cells and a preliminary molecular exploration of the estrogenic proliferative effects and related gene expression. Ecotoxicol Environ Saf. 2018 Sep 30;160:1-9. doi: 10.1016/j.ecoenv.2018.05.025. Epub 2018 May 21.
• [36] Evaluation of an imaging-based in vitro screening platform for estrogenic activity with OECD reference chemicals. Toxicol In Vitro. 2022 Jun;81:105348. doi: 10.1016/j.tiv.2022.105348. Epub 2022 Mar 18.
• [37] Estrogens reduce plasma histidine-rich glycoprotein (HRG) levels in a dose-dependent way. Thromb Haemost. 1995 Mar;73(3):484-7.
• [38] Oral contraceptives moderately effect bone resorption markers and serum-soluble interleukin-6 receptor concentrations. Calcif Tissue Int. 2002 Jan;70(1):11-21. doi: 10.1007/s002230020035. Epub 2001 Dec 21.
• [39] Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
• [40] Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity. Toxicology. 2014 Jun 5;320:46-55. doi: 10.1016/j.tox.2014.03.007. Epub 2014 Mar 28.
• [41] Differential effect of estrogen receptor alpha and beta agonists on the receptor for advanced glycation end product expression in human microvascular endothelial cells. Biochim Biophys Acta. 2005 Sep 30;1745(3):300-9. doi: 10.1016/j.bbamcr.2005.03.012. Epub 2005 Apr 12.
• [42] Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol Endocrinol. 2004 Feb;18(2):402-11. doi: 10.1210/me.2003-0202. Epub 2003 Nov 6.
• [43] Increased expression of estrogen receptor beta in human uterine smooth muscle at term. Eur J Endocrinol. 2000 Jan;142(1):92-9. doi: 10.1530/eje.0.1420092.
• [44] Estradiol upregulates activating transcription factor 3, a candidate gene in the etiology of hypospadias. Pediatr Dev Pathol. 2007 Nov-Dec;10(6):446-54. doi: 10.2350/06-04-0079.1.
• [45] Synthetic estrogen-mediated activation of ERK 2 intracellular signaling molecule. Gynecol Endocrinol. 2003 Oct;17(5):423-8. doi: 10.1080/09513590312331290338.
• [46] Novel full logistic model for estimation of the estrogenic activity of chemical mixtures. Toxicology. 2016 Jun 1;359-360:58-70. doi: 10.1016/j.tox.2016.06.017. Epub 2016 Jun 29.
• [47] Regulation of alternative splicing of liver scavenger receptor class B gene by estrogen and the involved regulatory splicing factors. Endocrinology. 2007 Nov;148(11):5295-304. doi: 10.1210/en.2007-0376. Epub 2007 Aug 2.
• [48] Effects of endocrine disrupting chemicals on the expression of RACK1 and LPS-induced THP-1 cell activation. Toxicology. 2022 Oct;480:153321. doi: 10.1016/j.tox.2022.153321. Epub 2022 Sep 13.
• [49] Detection of MDM2 alterations in cultured human hepatocytes treated with 17beta-estradiol or 17alpha-ethinylestradiol. Anticancer Res. 2002 May-Jun;22(3):1545-51.
• [50] Agonistic effects of diverse xenobiotics on the constitutive androstane receptor as detected in a recombinant yeast-cell assay. Toxicol In Vitro. 2018 Feb;46:335-349. doi: 10.1016/j.tiv.2017.09.014. Epub 2017 Sep 18.
• [51] Comparison of in vivo and in vitro reporter gene assays for short-term screening of estrogenic activity. Environ Sci Technol. 2002 Oct 15;36(20):4410-5. doi: 10.1021/es010323a.
• [52] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [53] Sulfation of environmental estrogen-like chemicals by human cytosolic sulfotransferases. Biochem Biophys Res Commun. 2000 Jan 7;267(1):80-4. doi: 10.1006/bbrc.1999.1935.
• [54] Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. J Pharmacol Exp Ther. 2004 Apr;309(1):156-64. doi: 10.1124/jpet.103.062091. Epub 2004 Jan 13.
• [55] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [56] Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol. Drug Metab Dispos. 2004 Nov;32(11):1299-303. doi: 10.1124/dmd.32.11..
• [57] Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6. Chem Res Toxicol. 2006 Feb;19(2):279-87. doi: 10.1021/tx050256o.
• [58] Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. Food Chem Toxicol. 2022 Apr;162:112869. doi: 10.1016/j.fct.2022.112869. Epub 2022 Feb 16.
• [59] Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40. doi: 10.1158/1078-0432.CCR-05-1778.
• [60] Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer. 2004 Sep 1;101(5):979-88. doi: 10.1002/cncr.20457.
• [61] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [62] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [63] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [64] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [65] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
• [66] Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
• [67] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [68] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [69] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [70] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [71] Drug Interactions Flockhart Table
• [72] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [73] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [74] Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol. 2010 Nov;161(5):1059-69. doi: 10.1111/j.1476-5381.2010.00946.x.
• [75] Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
• [76] A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
• [77] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [78] Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-B inactivation. Toxicol In Vitro. 2012 Apr;26(3):396-405.
• [79] Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro. PLoS One. 2011;6(9):e24831. doi: 10.1371/journal.pone.0024831. Epub 2011 Sep 14.
• [80] Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer. 2005 May 1;103(9):1800-9. doi: 10.1002/cncr.20973.
• [81] Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?. Clin Exp Immunol. 2008 Mar;151(3):391-8. doi: 10.1111/j.1365-2249.2007.03572.x. Epub 2008 Jan 10.
• [82] Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study. Arch Toxicol. 2022 Apr;96(4):1075-1087. doi: 10.1007/s00204-022-03245-x. Epub 2022 Feb 22.
• [83] Oral lichenoid eruption secondary to imatinib (Glivec). J Dermatolog Treat. 2004 Jul;15(4):253-5. doi: 10.1080/09546630410015556.
• [84] AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells. Cancer Sci. 2021 Jan;112(1):194-204. doi: 10.1111/cas.14698. Epub 2020 Nov 16.
• [85] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [86] Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004 Aug 15;104(4):1094-9. doi: 10.1182/blood-2003-12-4266. Epub 2004 Apr 20.
• [87] Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res. 2005 Feb 1;11(3):1336-41.
• [88] Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact. 2015 May 25;233:147-56. doi: 10.1016/j.cbi.2015.03.028. Epub 2015 Apr 8.
• [89] Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells. Oncotarget. 2015 Aug 21;6(24):20231-40. doi: 10.18632/oncotarget.4047.
• [90] Saikosaponin D disrupts platelet-derived growth factor- receptor/p38 pathway leading to mitochondrial apoptosis in human LO2 hepatocyte cells: a potential mechanism of hepatotoxicity. Chem Biol Interact. 2013 Oct 25;206(1):76-82. doi: 10.1016/j.cbi.2013.08.006. Epub 2013 Aug 28.
• [91] Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
• [92] Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res. 2010 Jan 1;70(1):150-9. doi: 10.1158/0008-5472.CAN-09-1449. Epub 2009 Dec 22.
• [93] The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. Blood. 2006 Nov 15;108(10):3538-47. doi: 10.1182/blood-2005-12-028456. Epub 2006 Jul 18.
• [94] Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia. Leukemia. 2003 Dec;17(12):2418-25. doi: 10.1038/sj.leu.2403152.
• [95] Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
• [96] Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
• [97] In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol. 2002 Jul;30(7):729-37. doi: 10.1016/s0301-472x(02)00836-6.
• [98] Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol. 2007 May;78(5):417-31. doi: 10.1111/j.1600-0609.2007.00835.x.
• [99] The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol. 2001 Mar;59(3):453-61. doi: 10.1124/mol.59.3.453.
• [100] Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis. Toxicol Lett. 2022 Jul 15;365:11-23. doi: 10.1016/j.toxlet.2022.06.001. Epub 2022 Jun 6.
• [101] Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.
• [102] A new strategy for the rapid identification and validation of direct toxicity targets of psoralen-induced hepatotoxicity. Toxicol Lett. 2022 Jun 15;363:11-26. doi: 10.1016/j.toxlet.2022.05.002. Epub 2022 May 18.
• [103] Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.
• [104] A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
• [105] Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem. 2004 Jul;50(7):1205-13. doi: 10.1373/clinchem.2004.031112. Epub 2004 Apr 23.
• [106] Identification of Genes That Modulate Susceptibility to Formaldehyde and Imatinib by Functional Genomic Screening in Human Haploid KBM7 Cells. Toxicol Sci. 2016 May;151(1):10-22. doi: 10.1093/toxsci/kfw032. Epub 2016 Mar 22.
• [107] Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. 2005 Sep 15;65(18):8224-32. doi: 10.1158/0008-5472.CAN-05-0303.
• [108] Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer. 2009 Jul;45(10):1877-89. doi: 10.1016/j.ejca.2009.04.005. Epub 2009 May 4.